Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience

Otto Metzger-Filho, Evandro de Azambuja, Marion Procter, Magalie Krieguer, Ian Smith, Jose Baselga, David Cameron, Michael Untch, Christian Jackisch, Richard Bell, Luca Gianni, Aron Goldhirsch, Martine Piccart, Richard D. Gelber

Research output: Contribution to journalArticlepeer-review

Abstract

This retrospective analysis conducted using data from patients enrolled onto the Herceptin Adjuvant has two objectives: The first is to evaluate the impact of the time interval between the end of adjuvant trastuzumab and distant recurrence (TDRI) upon overall survival (OS). The second is to describe the duration of trastuzumab-based regimens in the metastatic setting for patients previously treated with adjuvant trastuzumab. The first objective included 187 patients treated with adjuvant trastuzumab and diagnosed with distant recurrence at 4-year median follow-up. The second objective included data from questionnaires sent to investigators retreating patients with trastuzumab upon distant recurrence: 144 of 156 questionnaires were returned (93 %), and 90 patients were selected based on available clinical information and consent for subsequent studies. There was no statistically significant relationship between TDRI following 1 year of adjuvant trastuzumab and OS from distant recurrence: hazard ratio 0.991, p = 0.46. The median OS from distant recurrence was numerically longer among patients with a TDRI of ≥12 months (n = 103) than

Original languageEnglish
Pages (from-to)127-132
Number of pages6
JournalBreast Cancer Research and Treatment
Volume155
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Keywords

  • Breast cancer
  • Disease-free survival
  • HER2+

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience'. Together they form a unique fingerprint.

Cite this